Redmile Group, LLC - Director, 10%+ Owner at Fate Therapeutics Inc

Insider Transactions and Holdings

Entity Type
Company
Role
Director, 10%+ Owner
Stock Symbol
FATE on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
All Insider Reports
All Insider Reports

Redmile Group, LLC - trading volume in the past year for Fate Therapeutics Inc

Holdings reported by Redmile Group, LLC for Fate Therapeutics Inc

Class Num Shares Value Price $ Report Date Ownership Underlying Class Underlying Amount
Common Stock 13,180,388 $57.6 M $4.37 Dec 26, 2023 Indirect
Pre-Funded Warrants to Purchase Common Stock 3,893,674 $21.4 M $5.50 Mar 21, 2024 Indirect Common Stock
Stock Option (Right to Buy) 40,000 $109 K $2.73 Jun 7, 2024 Indirect Common Stock

Transactions reported by Redmile Group, LLC for Fate Therapeutics Inc

Sym Class Transaction % Value $ Price $ Shares Shares After Date Ownership